Noninvasive Imaging of CD206-Positive M2 Macrophages as an Early Biomarker for Post-Chemotherapy Tumor Relapse and Lymph Node Metastasis

Tumor relapse after initial regression post-chemotherapy is a major challenge in cancer treatment, as it usually leads to local-regional recurrence or inoperable distant metastasis. M2 macrophages diminish the tumor-inhibitory effect of chemotherapy and correlate with distant metastasis and poor prognosis. In this study, we investigated whether molecular imaging of M2 macrophages could serve as an early biomarker for tumor relapse after chemotherapy and tumor lymph node metastasis in preclinical mouse models. Methods: We developed M2 macrophage-targeted probes for near-infrared fluorescence (NIRF) imaging and single-photon emission computed tomography (SPECT) using an anti-CD206 monoclonal antibody. The specific targeting capacity and potential applications of the NIRF and SPECT probes were investigated in subcutaneous tumor and lymph node metastasis models of 4T1 murine breast cancer. Results: M2 macrophage infiltration was significantly increased in the 4T1 tumors that later underwent relapse but not in non-relapsing 4T1 tumors after cyclophosphamide treatment. Through NIRF imaging and SPECT using our synthesized probes, the infiltration of M2 macrophages in relapsing tumors and tumor lymph node metastasis could be sensitively detected. Importantly, early prediction of tumor relapse by molecular imaging of M2 macrophages resulted in an effective eradication of tumors upon combination with additional radiotherapy. Conclusion: Our findings demonstrate that M2 macrophage-targeted imaging allows for noninvasively predicting post-chemotherapy tumor relapse and sensitively detecting the metastatic lymph nodes in vivo. This imaging strategy could provide a better understanding of cancer progression, enable early prediction of tumor resistance, and have implications on the rational design of cancer therapeutics.

[1]  J. Li,et al.  Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. , 2016, Cancer research.

[2]  Fan Wang,et al.  Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model. , 2016, Biomaterials.

[3]  Fan Wang,et al.  Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition , 2016, Theranostics.

[4]  Fan Wang,et al.  Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy , 2015, The Journal of Nuclear Medicine.

[5]  I. Keklikoglou,et al.  Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. , 2015, Cancer research.

[6]  Murugesan V. S. Rajaram,et al.  γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206) , 2015, The Journal of Immunology.

[7]  Fan Wang,et al.  A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer. , 2015, Biomaterials.

[8]  Pradeep G. Bhambhvani,et al.  99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization , 2015, The Journal of Nuclear Medicine Technology.

[9]  Fan Wang,et al.  Molecular Imaging of Tumor-Infiltrating Macrophages in a Preclinical Mouse Model of Breast Cancer , 2015, Theranostics.

[10]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[11]  Fan Wang,et al.  Integrin αvβ6–Targeted SPECT Imaging for Pancreatic Cancer Detection , 2014, The Journal of Nuclear Medicine.

[12]  Fan Wang,et al.  Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models , 2014, The Journal of Nuclear Medicine.

[13]  H. Perlman,et al.  Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. , 2013, American journal of respiratory cell and molecular biology.

[14]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[15]  S. Amigorena,et al.  Inflammatory dendritic cells in mice and humans. , 2013, Trends in immunology.

[16]  Xiaoqiang Tang.  Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. , 2013, Cancer letters.

[17]  P. De Baetselier,et al.  SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis , 2013, The Journal of Nuclear Medicine.

[18]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[19]  S. Natsugoe,et al.  M2-Polarized Tumor-Associated Macrophage Infiltration of Regional Lymph Nodes Is Associated With Nodal Lymphangiogenesis and Occult Nodal Involvement in pN0 Pancreatic Cancer , 2013, Pancreas.

[20]  P. De Baetselier,et al.  Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. , 2012, Cancer research.

[21]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[22]  A. Jimeno,et al.  Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy , 2011, Nature Medicine.

[23]  M. Ewen,et al.  CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. , 2011, Cancer cell.

[24]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[25]  P. Allavena,et al.  Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages , 2011, Clinical & developmental immunology.

[26]  Michael Detmar,et al.  In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. , 2010, Cancer research.

[27]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[28]  M. Nimwegen,et al.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma , 2010, British Journal of Cancer.

[29]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[30]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[31]  G. Farrugia,et al.  CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. , 2010, Gastroenterology.

[32]  C. Liao,et al.  Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment , 2010, Proceedings of the National Academy of Sciences.

[33]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[34]  Fan Wang,et al.  In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. , 2009, Cancer biotherapy & radiopharmaceuticals.

[35]  J. Hughes,et al.  Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Anna M Wu,et al.  Antibodies for Molecular Imaging of Cancer , 2008, Cancer journal.

[37]  P. Pisa,et al.  Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages , 2008, Cancer Immunology, Immunotherapy.

[38]  Sanjiv S Gambhir,et al.  Molecular imaging techniques in body imaging. , 2007, Radiology.

[39]  D. Munn,et al.  The tumor‐draining lymph node as an immune‐privileged site , 2006, Immunological reviews.

[40]  C. Liu,et al.  Targeting tumor-associated macrophages as a novel strategy against breast cancer. , 2006, The Journal of clinical investigation.

[41]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[42]  J. Donohue,et al.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. , 2003, Archives of surgery.

[43]  Jonathan R Green,et al.  Antitumor effects of bisphosphonates , 2003, Cancer.

[44]  S. Hirakawa,et al.  The Formation of Lymphatic Vessels and Its Importance in the Setting of Malignancy , 2002, The Journal of experimental medicine.

[45]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[46]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[47]  Paul Symonds,et al.  Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis , 2001, The Lancet.

[48]  J. Mönkkönen,et al.  Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.

[49]  R. Weissleder.  Molecular imaging: exploring the next frontier. , 1999, Radiology.